Demographic and clinical factors impact PD survival. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
55/100
TAR DNA-binding protein 43 (TDP-43) aggregation is the most common pathological hallmark in frontotemporal dementia (FTD) and characterizes nearly all patients with motor neuron disease (MND). 3 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research on racial differences in Alzheimer disease (AD) dementia has increased in recent years. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Overall, 92% of patients had one or more dementia-related behaviors. 3 key findings →
Design: cross-sectional Participants: 5,776 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Black Americans are disproportionately affected by dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is emerging evidence that obstructive sleep apnea (OSA) is a risk factor for preclinical Alzheimer's disease (AD). 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Black patients (4806 [13.2%]; odds ratio [OR], 0.66; 95% CI, 0.59-0.72; P Conclusions and relevance Withdrawal of LST is common in sTBI and socioeconomic factors are associated with the decision to withdraw LST. 5 key findings →
Participants: 37,931 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
SubD was more prevalent than MDD in these primary care settings. 3 key findings →
Participants: 221 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results suggest that APOE epsilon4 and heavy drinking and heavy smoking lower the age of onset for AD in an additive fashion. 2 key findings →
Design: cross-sectional Participants: 397 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
While a growing body of evidence points to potentially modifiable individual risk factors for dementia, the built and social environments in which people develop and navigate cognitive decline are largely overlooked. 2 key findings →
Participants: 21,151 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The identification of biological and pathophysiological processes implicated in different forms of dementia is itself dependent on reliable descriptions of cognitive performance and capacities. 2 key findings →
Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
No large-scale characterizations of neurofilament light chain (NfL) have been conducted in diverse populations. 1 key finding →
Participants: 890 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In our population, the prevalence of stroke was higher than in previous studies. 2 key findings →
Design: case-control study Participants: 1,032 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We examined the association of type 2 diabetes mellitus to function in different cognitive systems in older black and white persons. 2 key findings →
Design: cohort study Participants: 1,437 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Cigarette smoking has been associated with dementia and dementia-related brain changes, notably gray matter (GM) volume atrophy. 3 key findings →
Participants: 698 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of dementia in this population is similar to that reported from other areas in mainland China and Taiwan with aging being a significant risk factor. 3 key findings →
Design: cross-sectional Participants: 16,095 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Variation in use of APMs in U.S. nursing homes based upon facility characteristics exemplifies the need for a more systematic protocol guiding the use of these medications, along with heightened regulatory policies and enforcement. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 1869 participants contributed 5309 observations (mean age 82.9 years, 21.0% Black, 9.3% met research-based dementia criteria). 5 key findings →
Participants: 1,869 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
. Longitudinally, older age (OR=1.14 [1.06-1.22], p<.001), higher levels of p-tau217 (OR=10.37 [3.00-35.02], p<.001) and higher neuropsychiatric symptoms (OR=1.19 [1.02-1.39], p=.023) were associated with higher odds of progression to dementia. 5 key findings →
Design: cross-sectional Participants: 104 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 9,361 SPRINT participants (mean age 67.1 ± 9.5 years, 36.7% female, 58.7% non-Hispanic White), 710 and 1,289 were new users of an ARB or ACEI. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Individuals with dementia and their care partners often report dissatisfaction with the disclosure process due to insufficient information and support. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
55/100
There was a significantly higher risk of developing a dementia diagnosis in Hispanic/Latino and NHB participants than NHW participants and comparably increased dementia hazard ratios in the Hispanic/Latino, NHB, and NHW APOE4 carriers than non-carriers (hazard ratio [HR] [95% confidence interval {CI}] 1.54 [1.25-1.91], 1.25 [1.00-1.57], and 1.55 [1.40-1.72]). 5 key findings →
Design: longitudinal study Participants: 9,784 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The built environment has direct and indirect effects on mental health. 1 key finding →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Among newly diagnosed ADRD patients (n = 1299), 26% filled an ADRD prescription ≤90 days and 36% ≤365 days after diagnosis. 5 key findings →
Participants: 1,299 Evidence: low
Full summary, score breakdown and related studies → Original source
Although a substantial body of research has identified brain MRI measures as important markers of Alzheimer's disease (AD) risk, progression, and treatment response, most of that research has been performed in non-Hispanic white American populations, leading to questions about the utility of the brain MRI measures among individuals of other races or ethnicities. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →